Hospital & Healthcare Services · Founded 2010 · www.manipalhospitals.com · BSE 544847 · NSE MANIPALHOS · ISIN INE459N01021
No Notes Added Yet
Business
Manipal Health Enterprises Ltd. (MHE) is one of India's leading multi-specialty healthcare providers. The company operates a chain of hospitals, offering comprehensive medical services across various specialties including cardiology, oncology, orthopedics, neurology, gastroenterology, and more. Its core business model involves generating revenue through patient fees for consultations, diagnostic services, surgical procedures, inpatient stays, pharmacy sales, and specialized treatments. Manipal Health focuses on providing accessible, high-quality, and affordable tertiary and quaternary healthcare.
Revenue Mix
While specific revenue percentages are not publicly detailed for this overview, MHE's revenue is primarily derived from:
In-patient services: This constitutes the largest portion, including income from patient admissions, surgeries, procedures, ICU stays, and room charges.
Out-patient services: Revenue from consultations, minor procedures, diagnostic tests (pathology, radiology), and follow-up visits.
Pharmacy sales: Revenue from dispensing medicines to both inpatients and outpatients.
Other services: Includes revenue from specialized clinics, health check-ups, and potentially medical tourism.
Industry
The Indian hospital and healthcare services industry is characterized by strong growth, driven by a large and aging population, rising disposable incomes, increasing health awareness, lifestyle diseases, and improving insurance penetration. The sector is fragmented, with a mix of large corporate chains, regional players, and standalone hospitals. Manipal Health Enterprises is positioned as one of the largest and most prominent multi-specialty hospital chains in India, with a significant presence particularly in South India and a growing footprint across other regions. It holds a strong brand reputation, often associated with its legacy in medical education.
MOAT
Brand Reputation: A strong and established brand name, rooted in the Manipal Education & Medical Group's legacy of quality healthcare and education, fosters trust and patient loyalty.
Scale & Network: A wide network of multi-specialty hospitals across India provides economies of scale in procurement, talent acquisition, and operational efficiencies.
Clinical Excellence & Talent: Ability to attract and retain highly skilled medical professionals and specialists due to its reputation, infrastructure, and referral network, ensuring high standards of clinical outcomes.
Patient Switching Costs: For complex or chronic conditions, patients often face high implicit switching costs once a relationship with doctors and a hospital system is established, due to continuity of care and trust.
Growth Drivers
Increasing Healthcare Expenditure: Rising GDP per capita, higher disposable incomes, and greater health insurance coverage are boosting demand for quality healthcare.
Demographic Trends: India's large and growing population, coupled with an increasing burden of chronic and lifestyle diseases, ensures a sustained demand for hospital services.
Expansion & Acquisitions: The company's strategy of organic (greenfield/brownfield) and inorganic (acquisitions of smaller hospitals or chains) expansion to new geographies and consolidating market share.
Medical Tourism: India's position as a hub for affordable and high-quality medical treatment attracts international patients, benefiting large hospital chains like Manipal.
Digital Health Adoption: Leverage of technology such as telemedicine, AI-driven diagnostics, and digital patient management systems to improve efficiency and reach.
Risks
Regulatory & Policy Risks: Government intervention in pricing of procedures, drugs, or medical devices, as well as evolving healthcare policies, can impact profitability.
Intense Competition: The sector faces strong competition from other large corporate hospital chains, regional players, and new entrants, potentially leading to pricing pressures.
Manpower Shortages & Costs: A shortage of skilled doctors, nurses, and paramedical staff, along with rising salary expectations, can increase operational costs.
High Capital Expenditure: The hospital business is highly capital-intensive, requiring continuous investment in infrastructure, medical equipment, and technology.
Medico-Legal & Ethical Risks: Hospitals are exposed to risks of malpractice suits, reputational damage from adverse events, and ethical scrutiny.
Economic Downturns: Recessions or significant economic slowdowns can reduce elective procedures and patient spending on healthcare.
Management & Ownership
Manipal Health Enterprises is promoted by the Manipal Education & Medical Group (MEMG), a conglomerate with a rich heritage in education and healthcare. The company is professionally managed with a blend of experienced healthcare administrators and medical professionals. The promoter group maintains significant control, providing strategic direction and leveraging the group's extensive network and expertise in the healthcare ecosystem.
Outlook
Manipal Health Enterprises is well-positioned to capitalize on the robust growth trajectory of the Indian healthcare sector, driven by strong underlying demand and increasing healthcare expenditure. Its established brand, extensive network, and focus on clinical excellence provide a solid foundation for future expansion, both organically and through strategic acquisitions. However, the company operates in a highly regulated and competitive environment. Sustaining growth will require effective navigation of potential regulatory headwinds, careful cost management, successful integration of new assets, and continued investment in technology and talent. Its ability to balance expansion with profitability, while maintaining quality standards, will be key to its long-term performance.
| #(Fig in Cr.) | Jun 2025 | Jun 2026 |
|---|---|---|
| Net Sales | 2238 | 3091 |
| Other Income | 48 | 75 |
| Total Income | 2286 | 3165 |
| Total Expenditure | 1651 | 2354 |
| Operating Profit | 635 | 811 |
| Interest | 132 | 293 |
| Depreciation | 141 | 187 |
| Exceptional Income / Expenses | -18 | -15 |
| Profit Before Tax | 344 | 315 |
| Provision for Tax | 90 | 72 |
| Profit After Tax | 254 | 243 |
| Adjustments | -4 | -12 |
| Profit After Adjustments | 250 | 232 |
| Adjusted Earnings Per Share | 2.2 | 2 |
| #(Fig in Cr.) | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 1260 | 1398 | 1567 | 1794 | 2025 | 1813 | 3975 | 4806 | 6172 | 8242 | 10336 | 5329 |
| Other Income | 53 | 47 | 39 | 29 | 35 | 58 | 109 | 88 | 97 | 157 | 185 | 123 |
| Total Income | 1313 | 1444 | 1605 | 1823 | 2060 | 1871 | 4084 | 4894 | 6269 | 8400 | 10521 | 5451 |
| Total Expenditure | 1106 | 1204 | 1335 | 1528 | 1622 | 1483 | 3076 | 3562 | 4492 | 6153 | 7725 | 4005 |
| Operating Profit | 207 | 240 | 270 | 295 | 438 | 388 | 1009 | 1332 | 1777 | 2247 | 2796 | 1446 |
| Interest | 99 | 155 | 170 | 180 | 211 | 205 | 326 | 329 | 455 | 512 | 864 | 425 |
| Depreciation | 100 | 134 | 163 | 213 | 175 | 183 | 256 | 315 | 397 | 507 | 680 | 328 |
| Exceptional Income / Expenses | -7 | -10 | -31 | -12 | 58 | -85 | 210 | -102 | -180 | 14 | -74 | -33 |
| Profit Before Tax | 1 | -59 | -94 | -109 | 110 | -86 | 637 | 586 | 745 | 1242 | 1178 | 659 |
| Provision for Tax | 28 | -19 | -12 | 26 | 46 | 32 | 90 | 157 | 212 | 161 | 262 | 162 |
| Profit After Tax | -27 | -40 | -82 | -135 | 64 | -117 | 547 | 429 | 533 | 1082 | 917 | 497 |
| Adjustments | -4 | 0 | 3 | -1 | -8 | -18 | -5 | -2 | 61 | -16 | -24 | -16 |
| Profit After Adjustments | -31 | -40 | -79 | -136 | 56 | -136 | 542 | 427 | 594 | 1065 | 892 | 482 |
| Adjusted Earnings Per Share | -0.3 | -0.4 | -0.8 | -1.3 | 0.5 | -1.3 | 4.8 | 3.8 | 5.2 | 46.1 | 7.6 | 4.2 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 25% | 29% | 42% | 23% |
| Operating Profit CAGR | 24% | 28% | 48% | 30% |
| PAT CAGR | -15% | 29% | 0% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | NA% | NA% | NA% | NA% |
| ROE Average | 13% | 17% | 18% | 6% |
| ROCE Average | 14% | 17% | 19% | 11% |
| #(Fig in Cr.) | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 1412 | 1387 | 1335 | 1203 | 1270 | 1132 | 2808 | 3242 | 4016 | 5847 | 8426 |
| Minority's Interest | 14 | 14 | 11 | 12 | 111 | 99 | 100 | 124 | 72 | 153 | 373 |
| Borrowings | 1010 | 1275 | 1585 | 1647 | 1708 | 1451 | 1604 | 1948 | 3700 | 4470 | 9949 |
| Other Non-Current Liabilities | 95 | 83 | 93 | 106 | 447 | 473 | 1095 | 1235 | 1313 | 1626 | 2625 |
| Total Current Liabilities | 331 | 315 | 441 | 545 | 641 | 869 | 1739 | 1214 | 1657 | 1795 | 3362 |
| Total Liabilities | 2863 | 3074 | 3465 | 3511 | 4177 | 4024 | 7346 | 7763 | 10757 | 13890 | 24735 |
| Fixed Assets | 1658 | 2104 | 2531 | 2558 | 3071 | 2239 | 4484 | 4742 | 8158 | 9826 | 18753 |
| Other Non-Current Assets | 570 | 281 | 338 | 368 | 428 | 657 | 1502 | 1426 | 541 | 1210 | 1873 |
| Total Current Assets | 634 | 689 | 596 | 586 | 678 | 716 | 1353 | 1588 | 2051 | 2848 | 4102 |
| Total Assets | 2863 | 3074 | 3465 | 3511 | 4177 | 4024 | 7346 | 7763 | 10757 | 13890 | 24735 |
| #(Fig in Cr.) | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | -13 | -10 | -5 | 27 | 73 | 64 | 22 | 57 | 68 | 361 | 291 |
| Cash Flow from Operating Activities | 67 | 110 | 408 | 270 | 409 | 426 | 805 | 1149 | 1389 | 1570 | 2078 |
| Cash Flow from Investing Activities | -169 | -227 | -544 | -127 | -324 | -188 | -1711 | -994 | -870 | -2658 | -7037 |
| Cash Flow from Financing Activities | 106 | 150 | 168 | -104 | -93 | -280 | 941 | -144 | -250 | 904 | 4954 |
| Net Cash Inflow / Outflow | 3 | 32 | 32 | 40 | -8 | -42 | 34 | 12 | 268 | -184 | -4 |
| Closing Cash & Cash Equivalent | -10 | 22 | 27 | 67 | 64 | 22 | 57 | 68 | 361 | 291 | 299 |
| # | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | -0.34 | -0.39 | -0.77 | -1.32 | 0.54 | -1.32 | 4.78 | 3.77 | 5.24 | 46.08 | 7.56 |
| CEPS(Rs) | 0.81 | 0.91 | 0.79 | 0.76 | 2.31 | 0.64 | 7.08 | 6.56 | 8.2 | 68.71 | 13.53 |
| DPS(Rs) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Book NAV/Share(Rs) | 15.52 | 13.39 | 12.89 | 11.6 | 12.22 | 10.99 | 24.59 | 28.38 | 35.38 | 251.17 | 70.8 |
| Core EBITDA Margin(%) | 12.2 | 13.83 | 14.76 | 14.84 | 19.9 | 18.21 | 22.63 | 25.89 | 27.21 | 25.35 | 25.26 |
| EBIT Margin(%) | 7.94 | 6.82 | 4.86 | 3.92 | 15.88 | 6.58 | 24.22 | 19.04 | 19.44 | 21.28 | 19.76 |
| Pre Tax Margin(%) | 0.07 | -4.24 | -6.02 | -6.09 | 5.44 | -4.72 | 16.03 | 12.18 | 12.07 | 15.07 | 11.4 |
| PAT Margin (%) | -2.15 | -2.89 | -5.25 | -7.52 | 3.15 | -6.47 | 13.75 | 8.93 | 8.64 | 13.12 | 8.87 |
| Cash Profit Margin (%) | 5.83 | 6.73 | 5.17 | 4.34 | 11.78 | 3.63 | 20.19 | 15.49 | 15.07 | 19.27 | 15.44 |
| ROA(%) | -1.13 | -1.36 | -2.52 | -3.87 | 1.66 | -2.86 | 9.62 | 5.68 | 5.76 | 8.78 | 4.75 |
| ROE(%) | -2.31 | -2.9 | -6.08 | -10.69 | 5.2 | -9.81 | 27.88 | 14.28 | 14.74 | 22.03 | 12.95 |
| ROCE(%) | 4.74 | 3.63 | 2.67 | 2.38 | 10.69 | 4.13 | 25.71 | 17.99 | 17.98 | 18.89 | 13.93 |
| Receivable days | 27.76 | 31.63 | 31.12 | 30.29 | 27.26 | 27.73 | 19.69 | 23.06 | 22.72 | 24.27 | 27.67 |
| Inventory Days | 9.39 | 10.05 | 8.96 | 7.8 | 7.48 | 6.57 | 4.6 | 5.33 | 4.92 | 5.21 | 5.33 |
| Payable days | 99.48 | 130.71 | 176.49 | 225.78 | 263.98 | 332.52 | 200.58 | 264.73 | 276.71 | 245.19 | 223.46 |
| PER(x) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Price/Book(x) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EV/Net Sales(x) | 0.9 | 0.99 | 1.07 | 0.96 | 0.89 | 0.89 | 0.47 | 0.43 | 0.59 | 0.55 | 0.99 |
| EV/Core EBITDA(x) | 5.47 | 5.76 | 6.2 | 5.86 | 4.13 | 4.18 | 1.87 | 1.55 | 2.05 | 2.01 | 3.65 |
| Net Sales Growth(%) | 22.63 | 10.95 | 12.08 | 14.54 | 12.83 | -10.44 | 119.23 | 20.9 | 28.42 | 33.55 | 25.4 |
| EBIT Growth(%) | 213.68 | -4.71 | -20.16 | -7.47 | 356.82 | -62.87 | 706.53 | -4.96 | 31.14 | 46.19 | 16.43 |
| PAT Growth(%) | -62.02 | -49.32 | -103.39 | -63.94 | 147.36 | -283.73 | 565.87 | -21.52 | 24.28 | 102.86 | -15.27 |
| EPS Growth(%) | -60.13 | -14 | -98.13 | -71.13 | 141.07 | -343.7 | 462.57 | -21.14 | 39.08 | 779.64 | -83.59 |
| Debt/Equity(x) | 0.79 | 0.97 | 1.24 | 1.45 | 1.43 | 1.39 | 0.71 | 0.67 | 0.98 | 0.82 | 1.23 |
| Current Ratio(x) | 1.91 | 2.19 | 1.35 | 1.08 | 1.06 | 0.82 | 0.78 | 1.31 | 1.24 | 1.59 | 1.22 |
| Quick Ratio(x) | 1.8 | 2.06 | 1.27 | 1 | 0.99 | 0.8 | 0.73 | 1.26 | 1.18 | 1.51 | 1.17 |
| Interest Cover(x) | 1.01 | 0.62 | 0.45 | 0.39 | 1.52 | 0.58 | 2.96 | 2.78 | 2.64 | 3.43 | 2.36 |
| Total Debt/Mcap(x) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| # | Jun 2026 | Aug 2026 |
|---|---|---|
| Promoter | 0 | 72.08 |
| FII | 0 | 3.65 |
| DII | 0 | 5.46 |
| Public | 0 | 18.81 |
| Others | 0 | 0 |
| Total | 0 | 100 |
| # | Jun 2026 | Aug 2026 |
|---|---|---|
| Promoter | 0 | 94.82 |
| FII | 0 | 4.8 |
| DII | 0 | 7.18 |
| Public | 0 | 24.74 |
| Others | 0 | 0 |
| Total | 0 | 131.54 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | +25% | +29% | +42% | +23% |
| Operating Profit CAGR | +24% | +28% | +48% | +30% |
| PAT CAGR | -15% | +29% | — | — |
| Share Price CAGR | — | — | — | — |
| ROE Average | +13% | +17% | +18% | +6% |
| ROCE Average | +14% | +17% | +19% | +11% |
| # | Jun 2026 | Aug 2026 |
|---|---|---|
| Promoter | 0 | 72.08 |
| FII | 0 | 3.65 |
| DII | 0 | 5.46 |
| Public | 0 | 18.81 |
| Others | 0 | 0 |
| Total | 100 | 100 |
| # | Jun 2026 | Aug 2026 |
|---|---|---|
| Promoter | 0 | 94.82 |
| FII | 0 | 4.8 |
| DII | 0 | 7.18 |
| Public | 0 | 24.74 |
| Others | 0 | 0 |
| Total | 0 | 131.54 |
* The pros and cons are machine generated.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
Your relationship manager will connect with you shortly.